Aboul Ella Hassanien (Abo)

Background: Although surgical resection is still the only curative maneuver in the treatment of colon cancer,
yet efforts have proved that systemic chemotherapy in the adjuvant setting improves the curative rate for those
patients with localized colon cancer. The combination of 5-fluorouracil (5-Fu) and leucovorin (LV) was the
reference treatment. However the advantage of infusional 5-Fu/LV with oxaliplatin (FolFox-4) as adjuvant
treatment for high risk colon cancer patients may change the paradigm soon. In this study we presented our
treatment results for patients with colon cancer treated with FolFox- 4 regimen as adjuvant treatment at Kasr Al
Aini Hospital.
Patients and Methods: We enrolled 55 patients who had undergone curative resection for sage II and III colon
cancer to receive FolFox-4 regimen for six months. The primary end point was disease –free survival
Results: Fifty five patients were included in this study. At the time of analysis (median follow up 18 months)
9 patients (16%) had disease relapse or metastasis. At 2.5 years DFS rates and OAS rates were 75% and 80%,
respectively. The treatment was generally well tolerated with most common grade 1 treatment-related adverse
event being peripheral neuropathy and hematological toxicity.
Conclusion: It is now acceptable to consider combination chemotherapy with FolFox -4 as adjuvant treatment
for high risk colon cancer patients after curative surgery at Kasr El Ainy center of Radiation Oncology and
nuclear medicine